Equities research analysts expect ConforMIS Inc (NASDAQ:CFMS) to post ($0.10) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for ConforMIS’s earnings, with estimates ranging from ($0.11) to ($0.09). ConforMIS reported earnings per share of ($0.16) in the same quarter last year, which would indicate a positive year-over-year growth rate of 37.5%. The firm is expected to report its next quarterly earnings results on Wednesday, February 5th.
On average, analysts expect that ConforMIS will report full year earnings of ($0.46) per share for the current year, with EPS estimates ranging from ($0.47) to ($0.45). For the next financial year, analysts anticipate that the company will post earnings of ($0.35) per share, with EPS estimates ranging from ($0.37) to ($0.34). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow ConforMIS.
ConforMIS (NASDAQ:CFMS) last released its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.02). The company had revenue of $17.30 million during the quarter, compared to analyst estimates of $17.80 million. ConforMIS had a negative net margin of 41.36% and a negative return on equity of 115.71%.
NASDAQ CFMS traded down $0.07 on Wednesday, hitting $1.49. 1,660,759 shares of the company were exchanged, compared to its average volume of 1,181,342. The company’s 50 day moving average price is $1.90 and its 200-day moving average price is $2.59. The company has a debt-to-equity ratio of 1.83, a current ratio of 3.11 and a quick ratio of 2.43. The firm has a market capitalization of $103.07 million, a P/E ratio of -2.01 and a beta of 2.29. ConforMIS has a twelve month low of $0.36 and a twelve month high of $4.83.
A number of institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can acquired a new stake in ConforMIS during the 2nd quarter worth about $27,000. LPL Financial LLC increased its holdings in shares of ConforMIS by 65.9% in the 2nd quarter. LPL Financial LLC now owns 16,752 shares of the medical instruments supplier’s stock valued at $73,000 after purchasing an additional 6,652 shares during the period. Steward Partners Investment Advisory LLC acquired a new position in shares of ConforMIS in the 2nd quarter valued at about $44,000. Private Advisor Group LLC purchased a new stake in shares of ConforMIS in the second quarter worth approximately $52,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of ConforMIS in the second quarter worth approximately $59,000. 45.69% of the stock is owned by hedge funds and other institutional investors.
ConforMIS Company Profile
Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.
Featured Article: Insider Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.